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Abstract 1 
Background: 2 
Systemic inflammation, even at low levels, is associated with significant derangement of 3 
measures of iron status, making diagnosis of iron deficiency difficult.  The objective of the 4 
present study was to create linear regression correction equations to adjust serum ferritin and 5 
iron using the acute phase proteins C-reactive protein (CRP) and albumin. 6 
 7 
Methods: 8 
Data from a cohort (1) of patients (n=7,226) in primary and secondary care who had serum 9 
ferritin, iron, CRP and albumin measured at the same time point were examined.  Linear 10 
regression coefficients calculated for CRP and albumin with serum iron and ferritin as the 11 
outcome variables.   Patients were categorised as iron deficient (ferritin <15µg/L, or serum 12 
iron <10 µmol/L).  The equation was then applied to a cohort (2) of patients with colorectal 13 
cancer who had ferritin and iron measured preoperatively (n=356).  14 
 15 
Results: 16 
In cohort 1 there was a significant difference in the proportions of patients with serum ferritin 17 
<15µg/L and serum iron <10µmol/L respectively when the unadjusted (7% and 55%), 18 
adjusted using CRP alone (13% and 26%), adjusted using albumin alone (11% and 37%), and 19 
using both CRP and albumin (24% and 15%) values were compared (both p<0.001).  In 20 
cohort 2 there was a significant difference in the proportions of patients with serum ferritin 21 
<15µg/L  and serum iron <10µmol/L respectively when the unadjusted (28% and 66%), 22 
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adjusted using CRP alone (39% and 57%), adjusted using albumin alone (39% and 59%), and 23 
using both CRP and albumin (46% and 44%) values were compared (p<0.001 and p<0.004). 24 
  25 
 26 
Conclusions: 27 
In both cohorts the greatest increase in the proportion of patients meeting definitions for iron 28 
deficiency was found when adjustment was made for both CRP and albumin together. Even 29 
low levels of inflammation had a significant effect on serum iron and ferritin values. 30 
 31 
 32 
Keywords 33 
Systemic inflammation, ferritin, iron deficiency, C-reactive protein, albumin, colorectal 34 
cancer  35 
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Introduction 36 
 37 
Iron deficiency remains a significant burden of disease and in both developing and developed 38 
countries [1].  Total serum iron can be used to assess iron status, however, in clinical practice, 39 
ferritin is a more robust measure of iron status.  Currently the World Health Organization 40 
(WHO) define adults with ferritin <15 µg/L as iron deficient [2].  However, ferritin is a 41 
positive acute phase reactant and therefore serum concentrations rise in the presence of 42 
systemic inflammation, leading to the possibility that patients may be truly iron deficient 43 
despite a serum ferritin >15 µg/L.   44 
Compounding matters, inflammation is associated with lower serum total iron and transferrin 45 
saturation, due to the action of hepcidin, itself driven by circulating IL 6 [3].  This often leads 46 
to a difficult to interpret picture of serum measures of iron status which may mask functional 47 
iron deficiency [4], thereby making it difficult to assess the need for iron replacement, and to 48 
monitor the effectiveness of iron supplementation. 49 
Therefore, attempts have been made to correct measures of iron status for the presence 50 
systemic inflammation, using exclusion criteria [5], correction factors [6], and novel markers 51 
of iron status [7].  Recently, the Biomarkers Reflecting Inflammation and Nutritional 52 
Determinants of Anemia (BRINDA) groups have used the acute phase markers C-reactive 53 
protein (CRP) and α-1-acid glycoprotein (AGP) to create linear correction regression 54 
equations to adjust serum ferritin by inflammation [8].  They argue that the significant effects 55 
of even low level inflammation make this the best method of adjustment [9].  However, as 56 
AGP is not widely clinical available at present, and compared to albumin is more expensive  57 
[10].  58 
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The effect on serum iron and ferritin of the combination of CRP and the widely clinically 59 
available negative acute phase protein albumin has also been quantified, having been shown 60 
to stratify serum iron and ferritin [11].  CRP is an opsonin and member of the pentraxin 61 
family synthesised by hepatocytes in response to stimulation by the proinflammatory 62 
cytokine IL 6, whilst the plasma transport protein albumin is redistributed due to changes in 63 
vascular permeability, and its synthesis is supressed by TNF and IL 1 [12].  To date, no 64 
regression correction equation to adjust serum iron or ferritin by these markers of systemic 65 
inflammation has been created.   66 
Therefore, the aim of the present study was to derive linear correction regression equations to 67 
adjust serum iron and ferritin by CRP and albumin, and then to apply this to a cohort of 68 
patients with colorectal cancer. 69 
  70 
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Patients and Methods 71 
 72 
Patients: 73 
The present study included two cohorts of patients.  The first (n=7,226), in which the 74 
regression correction equation was formulated, has been described previously [11].   75 
Briefly, details of all requests for serum iron or ferritin were obtained from the laboratory 76 
information systems of 4 Glasgow hospitals respectively for the period 1st August 2006 to 77 
31st July 2011.  These requests were made from secondary inpatient, secondary outpatient 78 
and primary care healthcare providers.  Iron and ferritin results were matched to CRP and 79 
albumin results obtained on the same calendar day using electronic laboratory patient 80 
identifiers. Any requests which were not accompanied by a CRP and albumin request were 81 
not included in the study. Where an individual had repeat measurements, only the first was 82 
included in the study to prevent the need for repeated measures analysis in the subgroup of 83 
included patients.   84 
The second (n=356) were patients with colorectal cancer undergoing potentially curative 85 
treatment at a single surgical centre in Glasgow, between 1st January 2008 and 30th June 2017 86 
who had a serum iron or ferritin measured in the preoperative period.  Patients who had not 87 
had either a serum iron or ferritin request were not included in the study. 88 
Ferritin was analysed using 2 step chemiluminescent microparticle immunoassay within the 89 
routine haematology laboratories.  Serum total iron (chemically using ferene), serum CRP (by 90 
the immunoturbidimetric method) and albumin (chemically using Bromocresol purple) were 91 
measured using an automated analyser (Architect, Abbot Diagnosis, Maidenhead, UK) in the 92 
routine biochemistry laboratories.  All sites used the same analytic materials and automated 93 
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platforms.  There were no sustained concerns regarding IQC performance requiring 94 
investigation into the performance of the assays. The A, B and C scores were within the EQA 95 
(NEQAS) targets during the study period.   96 
The audit was conducted with the intent of developing local guidelines and to aid in the 97 
interpretation of serum measurements of iron status and was approved by the health board 98 
(NHS Greater Glasgow and Clyde). 99 
 100 
Methods: 101 
The formulation of the regression correction equation was based on a modification of that 102 
used by the BRINDA group to correct ferritin for inflammation using CRP and AGP in 103 
asymptomatic populations [8, 13].  The equation used linear regression to adjust ferritin 104 
concentrations by the CRP and albumin concentrations on a continuous scale. 105 
The observed ferritin (Ferobs, normal range 41-400 µg/L), serum iron (Irobs, normal range 10-106 
30 µmol/L), CRP (CRPobs, normal range <10 mg/L) and albumin (Albobs, normal range 35-107 
50g/L) values were ln transformed to approximate a normal distribution.  Bivariate linear 108 
regression coefficients were calculated with ferritin as the outcome variable and CRP (β1) 109 
and albumin (β2) as each of the explanatory variables.  Multivariate linear regression was 110 
then used to calculate the variance inflation factor (VIF) as a measure of collinearity, with a 111 
value <5 allowing both variables to be included in the final equation.   112 
Internal reference values for CRP (CRPref) and albumin (Albref) were derived similarly to that 113 
used in the BRINDA methodology to prevent overcorrection for very low levels of 114 
inflammation.  ln CRPref  was calculated as the lowest decile of ln CRPobs in the cohort as 115 
CRP is a positive acute phase reactant, and ln Albref was calculated as the highest decile of ln 116 
Albobs in the cohort as albumin is a negative acute phase reactant.  These reference values 117 
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were subtracted from the observed CRP and albumin values within the equation, and the 118 
equation only applied to those patients with observed CRP above the internal reference cut 119 
off, and / or observed albumin below the internal reference cut off. 120 
The final ferritin correction equation is as follows: 121 
ln Feradj = ln Ferobs – (β1(ln CRPobs – ln CRPref)) – (β2(ln Albobs – ln Albref)) 122 
The final serum iron correction equation is as follows: 123 
ln Iradj = ln Irobs – (β1(ln CRPobs – ln CRPref)) – (β2(ln Albobs – ln Albref)) 124 
The calculated adjusted ferritin (ln Feradj) and serum iron (ln Irobs) was then back transformed 125 
to obtain an adjusted estimate for ferritin (Feradj) and serum iron (Iradj) respectively. 126 
 127 
Statistical analysis: 128 
In both cohorts.  Continuous data were presented as medians and interquartile range (IQR).  129 
The median unadjusted serum iron and ferritin were compared to the median serum iron and 130 
ferritin using adjustment by CRP alone, albumin alone, and both CRP and albumin using the 131 
related samples Friedmann’s two way analysis of variance by ranks. The proportion of 132 
patients defined as iron deficient (ferritin <15µg/L, or serum iron <10µmol/L) was calculated 133 
for unadjusted serum iron and ferritin and using adjustment for both CRP and albumin and 134 
compared using McNemar’s test. 135 
In the second cohort patients were classified as having anemia using haemoglobin (Hb) based 136 
on WHO guidelines for males; <130 g/L and females; <120 g/L [13].  Furthermore, anemic 137 
patients were classified as having microcytic anemia with mean corpuscular volume (MCV) 138 
<80 f/L, or normocytic anemia with MCV 80-100 f/L. 139 
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All analyses were performed using SPSS software (SPSS version 24, Chicago, Illinois, 140 
USA).  Two sided P values <0.05 were considered statistically significant.    141 
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Results 142 
 143 
Internal CRP and albumin reference values: 144 
The ln CRPref was calculated as lowest decile of ln CRPobs which was 0.262 (back 145 
transformed corresponding CRPobs = 1.3mg/L).  The ln Albref was calculated as the highest 146 
decile of ln Albobs which was 3.71 (back transformed corresponding Albobs = 40.9 g/L). 147 
 148 
Ferritin correction regression equation: 149 
Bivariate linear regression with ln Ferobs as outcome variable and ln CRPobs as the 150 
explanatory variable resulted in a regression coefficient (β1) of 0.331 (95% CI: 0.313, 0.348) 151 
and an intercept of 4.112 (95% CI: 4.057, 4.167).  Bivariate linear regression with ln Ferobs as 152 
outcome variable and ln Albobs as the explanatory variable resulted in a regression coefficient 153 
(β2) of -2.087 (95% CI: -2.212, -1.962) and an intercept of 12.157 (95% CI: 11.728, 12.586).  154 
At multivariate analysis there was no evidence of significant collinearity between ln CRPobs 155 
and ln Albobs (VIF = 1.5).   156 
The final series of regression correction equation was therefore as follows:   157 
ln Feradj = ln Ferobs – (0.331(ln CRPobs – 0.262)) – (-2.087(ln Albobs – 3.71)) 158 
IF ln CRPobs >0.262 AND ln Albobs <3.71 159 
Feradj = EXP (ln Feradj) 160 
 161 
 162 
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Serum iron correction regression equation: 163 
Bivariate linear regression with ln Irobs as outcome variable and ln CRPobs as the explanatory 164 
variable resulted in a regression coefficient (β1) of -0.261 (95% CI: -0.270, -0.251), and an 165 
intercept of 2.747 (95% CI: 2.716, 2.778).  Bivariate linear regression with ln Irobs as outcome 166 
variable and ln Albobs as the explanatory variable resulted in a regression coefficient (β2) of 167 
1.176 (95% CI: 1.100, 1.252), and an intercept of -1.949 (95% CI: -2.211, -1.687).  At 168 
multivariate analysis there was no evidence of significant collinearity between ln CRPobs and 169 
ln Albobs (VIF = 1.5).   170 
The final series of regression correction equation was therefore as follows:   171 
ln Iradj = ln Irobs – (-0.261(ln CRPobs – 0.262)) – (1.176(ln Albobs – 3.71)) 172 
IF ln CRPobs >0.262 AND ln Albobs <3.71 173 
Iradj = EXP (ln Iradj) 174 
 175 
Ferritin and serum iron adjustment in primary and secondary care patients: 176 
The primary and secondary care cohort included 7,226 patients of whom the majority 3,958 177 
(55%) were female and 3,260 (45%) were male, with a median age of 68 years (range: 16-178 
103 y).  Within the cohort the median CRPobs was 15.0 mg/L (range: 0.15-476 mg/L), and 179 
Albobs 32 g/L (range: 7-76 g/L). 180 
There was a significant decrease (Table 1) in the median serum ferritin (P<0.001) and a 181 
significant increase in the proportions of patients with serum ferritin <15 µg/L (P<0.001) 182 
when the unadjusted, adjusted using CRP alone, adjusted using albumin alone, and using both 183 
CRP and albumin values were compared. 184 
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There was a significant increase (Table 1) in the median serum iron (P<0.001) and a 185 
significant decrease in the proportions of patients with serum iron <10 µmol/L (P<0.001) 186 
when the unadjusted, adjusted using CRP alone, adjusted using albumin alone, and using both 187 
CRP and albumin values were compared. 188 
 189 
Concordance between serum ferritin and serum iron definitions of iron deficiency following 190 
adjustment: 191 
The proportion of patients in the primary and secondary care cohort found to not meet 192 
definitions of iron deficiency with both serum ferritin and serum iron (i.e. negative result 193 
agreement / true negative) increased from 43% using the unadjusted values to 66% when 194 
adjustment was made by both CRP and albumin (Table 2).  The proportion of patients found 195 
to meet definitions of iron deficiency with both serum ferritin and serum iron (i.e. positive 196 
result agreement / true positive) remained unchanged at 5% following the same adjustment. 197 
 198 
Ferritin and serum iron adjustment in patients with colorectal cancer: 199 
There were 356 patients with UICC stage I-IV colorectal cancer who underwent surgery with 200 
curative intent at a single centre and had a preoperative serum ferritin or measured, of which 201 
67 had serum iron measured, 307 had CRP measured, and 236 had both CRP and albumin 202 
measured (Table 2).  Within the cohort there were 161 females (45%) and 195 males (55%), 203 
with a median age of 71 years (range: 27-90 y), and the majority having colonic (n=259, 204 
73%) and node negative (n=209, 59%) disease.  205 
There was a significant decrease (Table 3) in the median serum ferritin (P<0.001) and a 206 
significant increase in the proportions of patients with serum ferritin <15 µg/L (P<0.001) 207 
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when the unadjusted, adjusted using CRP alone, adjusted using albumin alone, and using both 208 
CRP and albumin values were compared. 209 
There was a significant increase (Table 3) in the median serum iron (P<0.001) and a 210 
significant decrease in the proportions of patients with serum iron <10 µmol/L (P<0.001) 211 
when the unadjusted, adjusted using CRP alone, adjusted using albumin alone, and using both 212 
CRP and albumin values were compared. 213 
 214 
Association between adjusted iron deficiency and anaemia in patients with colorectal cancer: 215 
Of the cohort of patients with colorectal cancer, 354 had serum ferritin, Hb and MCV 216 
measured allowing them to be grouped as having no anemia (n=174, 50%), microcytic 217 
anemia (n=41, 11%) or normocytic anemia (n=139, 39%) (Table 4).  There was a significant 218 
association between the anemia groups and age (P<0.001), American Society of 219 
Anesthesiology (ASA) grade (P<0.001), tumor site (P<0.001), TNM stage (P=0.010), tumor 220 
differentiation (P<0.001), and modified Glasgow Prognostic Score (mGPS) (P<0.004).  The 221 
proportion of patients found to have serum ferritin <15 µg/L was significantly different 222 
amongst the no anemia, microcytic anemia and normocytic anemia groups respectively 223 
whether unadjusted (P<0.001), adjusted by CRP alone (P<0.001), adjusted by albumin alone 224 
(P<0.001) or adjusted by both CRP and albumin (P<0.001) values were considered.  The 225 
proportion of patients found to have serum iron <10 µmol/L was significantly different 226 
amongst the no anaemia, microcytic anemia and normocytic anemia groups using the 227 
unadjusted values only (P=0.007)  228 
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Discussion 229 
 230 
The results of the present study report linear regression based correction equations to adjust 231 
observed serum iron and ferritin concentrations based on CRP and albumin in a cohort of 232 
primary and secondary care patients, and patients with colorectal cancer. 233 
The BRINDA Working Group have previously reported the use of a linear regression based 234 
correction equation for ferritin adjusted by CRP and AGP in populations across multiple 235 
countries [8].  Unlike serum albumin, AGP is used to define the “phase” of inflammation, 236 
rather than its magnitude making estimation both dependent on their concentrations and the 237 
phase in which the patient is found [15].  In addition, unlike albumin, AGP is not at present 238 
widely used in clinical practice, especially in the developing countries from which many of 239 
the BRINDA cohorts were derived [13].  240 
Although prior studies have suggested the use of correction factors based cut off values of 241 
acute phase proteins [6], or changing the ferritin concentration threshold for the diagnosis of 242 
iron deficiency to <30 µg/L to account for inflammation [14],  the BRINDA group show that 243 
serum ferritin concentrations are significantly affected even at low levels of inflammation, 244 
below those cut off values used previously [9].  The same is true for serum total iron [11], 245 
which in addition is highly variable from individual to individual, within individuals, and is 246 
also significantly affected by dietary intake [3].    247 
These findings are in keeping with the results of the present study and the previously reported 248 
results from this cohort in which patients were grouped by CRP and albumin [11].  In it, 13% 249 
of patients with CRP <10mg/L and albumin >35g/L (therefore thought to be minimally 250 
inflamed), were still found to have ferritin <15 µg/L.  Although the use of such groupings to 251 
account for inflammatory status is useful, the BRINDA group suggest that regression based 252 
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correction, as in the present paper, provides greater accuracy.  Particularly, as with CRP and 253 
AGP in the BRINDA papers, because even low and “sub-clinical” levels of systemic 254 
inflammation can significantly alter serum measures of iron status [16].  This study differs 255 
from our previously reported work by using continuous regression equation adjustment rather 256 
than grouping in attempt to account for the aforementioned “sub-clinical” inflammation.  257 
Indeed, in the present study the CRP and albumin reference values used to prevent over-258 
correction for low level inflammation were 1.3 mg/L and 40.9 g/L respectively, much 259 
different from “minimally inflamed” group threhsolds used previously.   260 
The greatest difference in the proportion of iron deficient patients was found when 261 
adjustment was made for both CRP and albumin together.   It may be that this relates to the 262 
different half-lives of CRP and albumin, with CRP peaking around 48 to 72 hours following 263 
an inflammatory insult and then ending to decrease rapidly, with albumin taking much longer 264 
to return to reference range concentrations [17].  It could be considered in this context that 265 
albumin is perhaps a longer term index of inflammation and CRP a short term marker, hence 266 
the additive effect with regard to ferritin and iron correction. 267 
The present study reports the application of CRP and albumin based regression correction to 268 
a small cohort of patients with colorectal cancer.  A high proportion of patients with 269 
normocytic anaemia (57%) and without anaemia (29%) were found to be apparently iron 270 
deficient.  This may represent patients who have functional iron deficiency related to the 271 
presence of a host systemic inflammatory response to cancer.  At present there is little data to 272 
suggest whether iron replacement therapy will be of use in those patients with inflammation 273 
who meet definitions of iron deficiency following mathematical adjustment compared to 274 
those who do not.  This is indeed an area requiring prospective investigation, and hopefully 275 
the use of such correction strategies might allow patient stratification in such studies. 276 
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The present study has a number of limitations.  The lack of clinical data regarding reasons for the 277 
investigation of iron status in the first cohort means that there were no data relating to the presence of 278 
underlying autoimmune disease or liver disease or markers of synthetic liver function associated with 279 
treated systemic inflammation or altered iron homeostasis.  Within the second cohort, the selection of 280 
patients for whom ferritin had been requested may introduce selection bias, although the prevalence of 281 
anaemia, and its subtypes is in keeping with recently published reports [18]. 282 
In summary the present study reports a regression correction equation to adjust serum iron 283 
and ferritin concentrations based on CRP and albumin in a cohort of patients in primary and 284 
secondary care, and in a cohort of patients with colorectal cancer.  In both cohorts the greatest 285 
difference in the proportion of iron deficient patients was found when adjustment was made 286 
for both CRP and albumin together.  Even very low levels of inflammation were associated 287 
with significant perturbment of ferritin.  Although the presented regression equations do not 288 
produce perfect agreement amongst different measures of iron status, their use did improve 289 
concordance and suggest that with ongoing refinement further similar techniques may prove 290 
useful in the absence of novel markers of iron status.  291 
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Tables and Footnotes 
 
Table 1 Estimated prevalence of iron deficiency; serum ferritin <15µg/L or serum iron <10 
µmol/L, based on regression correction using serum C-reactive protein (CRP) and albumin in 
an unselected cohort of primary and secondary care patients.1 
Iron measure Unadjusted CRP only Albumin only CRP and 
albumin 
P 
Serum Ferritin      
n 7226 7219 6406 6406 - 
Ferritin, µg/L, 162 (57-385) 69 (28-161) 89 (35-203) 38 (15-92) <0.0012 
Ferritin <15 µg/L, 
n (%) 
479 (7) 939 (13) 679 (11) 1557 (24) <0.0013 
      
Serum Iron      
n 7182 7182 6371 6371 - 
Iron, µmol/L, 8 (4-15) 15 (10-23) 12 (7-19) 20 (13-32) <0.0012 
Iron <10 µmol/L, 
n (%) 
4027 (55) 1877 (26) 2705 (37) 925 (15) <0.0013 
1Continuous values are presented as median and IQR, 2Medians of all four adjustment 
methods compared using related samples Friedmann’s two way analysis of variance by ranks, 
3Proportions of “Unadjusted” and “CRP and albumin adjusted” methods compared using 
McNemar’s test . CRP, C-reactive protein; IQR, interquartile range. 
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Table 2 Concordance between serum ferritin and serum iron definitions of iron deficiency 
before and after adjustment by serum C-reactive protein (CRP) and albumin: 
Unadjusted    
  Iron <10µmol/L  
  No, n (%) Yes, n (%) 
Ferritin <15µg/L No, n(%) 3059 (43) 3644 (51) 
 Yes, n(%) 96 (1) 383 (5) 
Adjusted by CRP and 
albumin 
   
  Iron <10µmol/L  
  No, n (%) Yes, n (%) 
Ferritin <15µg/L No, n(%) 4253 (66) 630 (10) 
 Yes, n(%) 1241 (19) 294 (5) 
CRP C-reactive protein 
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Table 3 Estimated prevalence of iron deficiency; serum ferritin <15µg/L, or serum iron 
<10µmol/L; based on regression correction using serum C-reactive protein (CRP) and 
albumin in patients undergoing surgery for colorectal cancer.1 
Iron measure Unadjusted CRP only Albumin only CRP and 
albumin 
P 
Serum Ferritin      
n 356 307 236 236 - 
Ferritin, µg/L 38 (13-93) 24 (8-66) 24 (9-70) 18 (6-52) <0.0012 
Ferritin <15 µg/L, 
n (%) 
100 (28) 120 (39) 91 (39) 107 (46) <0.0013 
      
Serum Iron      
n 67 58 46 46 - 
Iron, µmol/L 5 (3-13) 8 (3-19) 6 (4-17) 11 (5-26) <0.0012 
Iron <10 µmol/L, 
n (%) 
44 (66) 33 (57) 27 (59) 20 (44) 0.0043 
1Continuous values are presented as median and IQR. 2Medians of all four adjustment 
methods compared using related samples Friedmann’s two way analysis of variance by ranks, 
3Proportions of “Unadjusted” and “CRP and albumin adjusted” methods compared using 
McNemar’s test . CRP, C-reactive protein; IQR, interquartile range. 
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Table 4 Association between anemia1 and estimated prevalence of iron deficiency (ferritin 
<15µg/L) based on regression correction using serum C-reactive protein (CRP) and albumin 
in patients undergoing surgery for colorectal cancer. 
Anemia1  None Microcytic2 Normocytic3 P 
n  174 (50) 41 (11) 139 (39) - 
      
Demographic      
Sex, n (%)     0.3984 
 Male 89 (51) 24 (59) 81 (58)  
 Female 85 (49) 17 (41) 58 (42)  
Age, n (%)     <0.0015 
 <65 66 (38) 16 (39) 24 (17)  
 65-70 73 (42) 12 (29) 51 (37)  
 >70 35 (20) 13 (32) 64 (46)  
ASA, n (%)     <0.0015 
 1 42 (28) 6 (16) 12 (11)  
 2 63 (43) 17 (45) 50 (45)  
 3 39 (26) 14 (37) 45 (40)  
 4 4 (3) 1 (2) 5 (5)  
nCRT, n (%)     0.7394 
 Yes 8 (5) 2 (5) 9 (7)  
 No 165 (95) 38 (95) 127 (93)  
Pathological      
Tumor site, n (%)     <0.0014 
 Colon 106 (61) 39 (95) 113 (82)  
 Rectum 67 (39) 2 (5) 25 (18)  
TNM stage, n (%)     0.0105 
 0/1 44 (26) 1 (3) 15 (11)  
 2 66 (38) 18 (45) 64 (47)  
 3 60 (34) 18 (45) 51 (38)  
 4 3 (2) 3 (7) 6 (4)  
Differentiation, n (%)     <0.0014 
 Well / Mod 166 (97) 29 (74) 118 (88)  
 Poor 5 (3) 10 (26) 16 (12)  
Venous invasion, n (%)     1.0004 
 Present 111 (64) 25 (64) 88 (64)  
 Absent 62 (36) 14 (36) 49 (36)  
Systemic inflammation      
mGPS     0.0045 
 0 114 (80) 25 (76) 76 (72)  
 1 18 (13) 3 (9) 5 (5)  
 2 10 (7) 5 (15) 24 (23)  
Serum Ferritin      
Unadjusted, n (%) 
(n=354) 
    <0.0014 
 <15µg/L 26 (15) 28 (68) 46 (33)  
 ≥15µg/L 148 (85) 13 (32) 93 (67)  
CRP only, n (%)(n=305)     <0.0014 
 <15µg/L 33 (22) 31 (80) 56 (48)  
 ≥15µg/L 117 (78) 8 (21) 60 (52)  
Albumin only, n (%) 
(n=234) 
    <0.0014 
 <15µg/L 25 (21) 23 (85) 43 (50)  
 ≥15µg/L 96 (79) 4 (15) 43 (50)  
CRP and albumin, n 
(%)(n=230) 
    <0.0014 
 <15µg/L 34 (29) 24 (89) 48 (57)  
 ≥15µg/L 84 (71) 3 (11) 37 (44)  
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Serum Iron      
Unadjusted, n (%) 
(n=66) 
    0.0074 
 <10µmol/L 5 (36) 12 (92) 27 (69)  
 ≥10µmol/L 9 (64) 1 (8) 12 (31)  
CRP only, n (%) (n=57)     0.1294 
 <10µmol/L 5 (36) 8 (73) 20 (63)  
 ≥10µmol/L 9 (64) 3 (27) 12 (37)  
Albumin only, n (%) 
(n=45) 
    0.0554 
 <10µmol/L 5 (36) 6 (86) 16 (67)  
 ≥10µmol/L 9 (64) 1 (14) 8 (33)  
CRP and albumin, n (%) 
(n=45) 
    0.1734 
 <10µmol/L 4 (29) 5 (71) 11 (46)  
 ≥10µmol/L 10 (71) 2 (29) 13 (54)  
1 Males = Hb <130g/L, females <120g/L, 2Anemia and MCV <80fL, 3Anemia and MCV 80-100fL.  4Chi square 
test, 5Chi square test for linear association.  ASA, American Society of Anesthesiology; mGPS, modified 
Glasgow Prognostic Score; MCV, mean corpuscular volume; nCRT, neoadjuvant chemoradiotherapy; TNM, 
tumor nodes metastasis stage. 
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Patients in primary or secondary 
care with samples sent to 4 hospital 
laboratories and results for: 
(iron OR ferritin) AND markers of 
systemic inflammation 
N=7,226 
Patient samples with 
results of serum iron  
N=7182 
Patient samples with 
results ferritin 
N=7226 
Patient samples with 
results for ferritin AND 
CRP 
N=7,219 
Patient samples with 
results for ferritin AND 
CRP AND albumin 
N=6,406 
Patient samples with 
results for serum iron 
AND CRP 
N=7,182 
Patient samples with 
results for serum iron 
AND CRP AND albumin 
N=6,371 
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Supplementary data 2: Patient Flow Chart – Cohort 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Patients who underwent elective 
surgery for colorectal cancer with 
curative intent at a single centre, 
Jan ’08 – June ‘17 
N=790 
Patients who had 
preoperative serum 
ferritin measured 
N=356 
Patients who had 
preoperative serum 
ferritin AND CRP 
measured 
N=307 
Patient who had 
preoperative serum 
ferritin AND CRP AND 
albumin measured 
N=236 
Patients who had 
preoperative serum iron 
measured 
N=67 
Patients who had 
preoperative serum iron 
AND CRP measured 
N=58 
Patient who had 
preoperative serum iron 
AND CRP AND albumin 
measured 
N=46 
